Allergic bronchopulmonary fungal disease without clinical asthma.

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Allergic bronchopulmonary fungal disease without clinical asthma.

During a retrospective survey of patients with pulmonary shadows and blood eosinophilia between the years 1965 and 1980, 42 patients were found with allergic bronchopulmonary fungal disease. Eleven of these had no clinical evidence of asthma. Three of these 11 had hypersensitivity to fungi other than Aspergillus sp. In the absence of asthma there was some difficulty in making a diagnosis, parti...

متن کامل

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis.

Severe asthma with fungal sensitisation and allergic bronchopulmonary aspergillosis encompass two closely related subgroups of patients with severe allergic asthma. Pulmonary disease is due to pronounced host inflammatory responses to noninvasive subclinical endobronchial infection with filamentous fungi, usually Aspergillus fumigatus. These patients usually do not achieve satisfactory disease ...

متن کامل

General overview of fungal allergic asthma

Asthma is a complicated disorder, whose prevalence has increased over the past few decades.Asthma is characterized by infiltration of inflammatory leukocytes along with enhancedproinflammatory cytokines and chemokines. Fungi are now far more widely being considered as thedominant extrinsic trigger for asthma. Fungi are linked to the severity of asthma in many ways. Somedifferences between studi...

متن کامل

Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization.

Rationale and objectives. Severe asthma with fungal sensitization (SAFS) and allergic bronchopulmonary aspergillosis (ABPA) are progressive allergic fungal lung diseases whose effective treatment remains to be established. Current treatment with itraconazole is associated with a 40% failure rate and adverse events (AEs). We assessed the effect of voriconazole or posaconazole as second- and thir...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Thorax

سال: 1981

ISSN: 0040-6376

DOI: 10.1136/thx.36.5.345